Form D · Biotechnology

Abogen, Inc.

Portland, ME · CIK 0001700326

Offering snapshot reported Jul 31, 2017 · SEC filing

Reported sold
$25K
Offering amount: $4M
Investors reported
1
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Jul 28, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 31, 2017Initial$25,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$520K (estimated)
Finders' fees
$0
Form D file number
021-291763
PHX Financial is to receive 10% of aggregate gross proceed as commission, and 3% as non-accountable cash expenses. PHX is separately compensated for general investment banker services, not variable with amount of securities sold.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
PHX Financial, Inc. d/b/a Phoenix Financial Services144403

Source: Form D, filed Jul 31, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stephen Andrews Director, Executive, Promoter
Youssef Biahillah Director, Executive, Promoter
Jacques Essinger Director
Fred Heimann Director
Manasi Pancholy Jain Executive
Ken Martin Director
Michael Steele Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
477 Congress Street, Suite 1010
Portland, ME, 04101